1
|
Lao P, Young CB, Ezeh C, Lacayo B, Seblova D, Andrews RM, Gibbons L, Kraal AZ, Turney I, Deters KD, Dotson V, Manly JJ, Barnes LL, Zahodne LB. Loneliness, cerebrovascular and Alzheimer's disease pathology, and cognition. Alzheimers Dement 2024. [PMID: 39234651 DOI: 10.1002/alz.14196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 07/02/2024] [Accepted: 07/24/2024] [Indexed: 09/06/2024]
Abstract
INTRODUCTION Loneliness has a rising public health impact, but research involving neuropathology and representative cohorts has been limited. METHODS Inverse odds of selection weights were generalized from the autopsy sample of Rush Alzheimer's Disease Center cohorts (N = 680; 89 ± 9 years old; 25% dementia) to the US-representative Health and Retirement Study (N = 8469; 76 ± 7 years old; 5% dementia) to extend external validity. Regressions tested cross-sectional associations between loneliness and (1) Alzheimer's disease (AD) and cerebrovascular pathology; (2) five cognitive domains; and (3) relationships between pathology and cognition, adjusting for depression. RESULTS In weighted models, greater loneliness was associated with microinfarcts, lower episodic and working memory in the absence of AD pathology, lower working memory in the absence of infarcts, a stronger association of infarcts with lower episodic memory, and a stronger association of microinfarcts with lower working and semantic memory. DISCUSSION Loneliness may relate to AD through multiple pathways involving cerebrovascular pathology and cognitive reserve. HIGHLIGHTS Loneliness was associated with worse cognition in five domains. Loneliness was associated with the presence of microinfarcts. Loneliness moderated cognition-neuropathology associations. Transportability methods can provide insight into selection bias.
Collapse
Affiliation(s)
- Patrick Lao
- Department of Neurology, Columbia University, New York, New York, USA
| | - Christina B Young
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
| | - Chima Ezeh
- Department of Neurology, Columbia University, New York, New York, USA
| | - Bayardo Lacayo
- Department of Neurology, Columbia University, New York, New York, USA
| | - Dominika Seblova
- Second Faculty of Medicine, Charles University Prague, Prague, Czech
| | - Ryan M Andrews
- Department of Epidemiology, Boston University, Boston, Massachusetts, USA
- Department of Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany
| | - Laura Gibbons
- General Internal Medicine, School of Medicine, University of Washington, Seattle, Washington, USA
| | - A Zarina Kraal
- Department of Neurology, Columbia University, New York, New York, USA
| | - Indira Turney
- Department of Neurology, Columbia University, New York, New York, USA
| | - Kacie D Deters
- Department of Integrative Biology and Physiology, College of Life Sciences, University of California Los Angeles, Los Angeles, California, USA
| | - Vonetta Dotson
- Department of Psychology and Gerontology Institute, Georgia State University, Atlanta, Georgia, USA
| | - Jennifer J Manly
- Department of Neurology, Columbia University, New York, New York, USA
| | - Lisa L Barnes
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA
| | - Laura B Zahodne
- Department of Psychology, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|
2
|
Perna A, Montine KS, White LR, Montine TJ, Cholerton BA. Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia. Neurotherapeutics 2023; 20:1641-1652. [PMID: 37733209 PMCID: PMC10684852 DOI: 10.1007/s13311-023-01441-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/09/2023] [Indexed: 09/22/2023] Open
Abstract
Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other neurotoxic events. A major complication in identifying effective treatment targets is the frequent co-occurrence of multiple neurodegenerative processes, occurring either in parallel or sequentially. The path towards developing effective treatments for Alzheimer's disease (AD) and other dementias has been relatively slow and until recently has focused on disease symptoms. Aducanumab and lecanemab, recently approved by the FDA, are meant to target disease structures but have only modest benefit on symptom progression and remain unproven in reversing or preventing dementia. A third, donanemab, appears more promising but awaits FDA approval. Ongoing trials include potential cognition enhancers, new combinations of known drugs for synergistic effects, prodrugs with less toxicity, and increasing interest in drugs targeting neuroinflammation or microbiome. Scientific and technological advances offer the opportunity to move in new therapy directions, such as modifying microglia to prevent or suppress underlying disease. A major challenge, however, is that underlying comorbidities likely influence the effectiveness of therapies. Indeed, the full range of comorbidity, today only definitively identified postmortem, likely contributes to failed clinical trials and overmedication of older adults, since it is difficult to exclude (during life) people unlikely to respond. Our current knowledge thus signals that a paradigm shift towards individualized and multimodal treatments is necessary to effectively advance the field of dementia therapeutics.
Collapse
Affiliation(s)
- Amalia Perna
- Department of Pathology, Stanford University, 300 Pasteur Dr., Stanford, CA, 94305, USA.
| | - Kathleen S Montine
- Department of Pathology, Stanford University, 300 Pasteur Dr., Stanford, CA, 94305, USA
| | - Lon R White
- Pacific Health Research and Education Institute, Honolulu, HI, USA
| | - Thomas J Montine
- Department of Pathology, Stanford University, 300 Pasteur Dr., Stanford, CA, 94305, USA
| | - Brenna A Cholerton
- Department of Pathology, Stanford University, 300 Pasteur Dr., Stanford, CA, 94305, USA
| |
Collapse
|
3
|
Fletcher JR. Cognitivism ageing: The Alzheimer conundrum as switched ontology & the potential for a new materialist dementia. J Aging Stud 2023; 66:101155. [PMID: 37704273 DOI: 10.1016/j.jaging.2023.101155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 04/08/2023] [Accepted: 06/18/2023] [Indexed: 09/15/2023]
Abstract
Following recent regulatory approvals for anti-Alzheimer's monoclonal antibodies, this paper considers the contemporary role of cognitivism in defining the ontological commitments of dementia research, as well as movements away from cognitivism under the umbrella of 4E cognitive science. 4E cognitive theories, extending cognition into bodies, their environs, and active relations between the two, share potentially fruitful affinities with new materialisms which focus on the co-constitution of matter in intra-action. These semi-overlapping conceptual positions furnish some opportunity for an ontological alternative to longstanding cognitivist commitments, particularly to the isolated brain as a material catalyst for commercial interventions. After outlining mainstream cognitivism and its shortcomings, I explore 4E and new materialism as possibly transformative conceptual schemas for dementia research, a field for which cognitivist imaginings of cognitive decline in later life have profound and often regrettable ramifications. To realise this new materialist dementia, I sketch out a cognitive ontology based on Barad's agential realism. This facilitates a reassessment of the biggest conundrum in dementia research - the lack of neat correlation between (apparently material) neuropathology and (apparently immaterial) cognitive impairment - alongside the continued failure of efforts to develop effective interventions. It also gives social researchers working on cognitive decline in later life an opportunity to reappraise the nature of social science as a response to such phenomena. If cognition and cognitive ageing are reimagined as an emergent characteristic of intra-acting matter, then new materialist social science might be at least as conducive to salutogenic interventions as the neuropsychiatric technoscience that dominates the contemporary dementia research economy despite continual failures. I argue that a new materialist cognitive ontology could help us think beyond an ageing cognitivism and, by extension, beyond the Alzheimer conundrum.
Collapse
Affiliation(s)
- James Rupert Fletcher
- Wellcome Fellow, Department of Sociology, University of Manchester, 3rd Floor, Arthur Lewis Building, Oxford Road, Manchester M13 9PL, UK.
| |
Collapse
|
4
|
Abstract
This review deals with an unwelcome reality about several forms of dementia, including Alzheimer's disease- that these dementias are caused, in part or whole, by the aging of the vasculature. Since the vasculature ages in us all, dementia is our fate, sealed by the realit!ies of the circulation; it is not a disease with a cure pending. Empirically, cognitive impairment before our 7th decade is uncommon and considered early, while a diagnosis in our 11th decade is late but common in that cohort (>40%). Projections from earlier ages suggest that the prevalence of dementia in people surviving into their 12th decade exceeds 80%. We address the question why so few of many interventions known to delay dementia are recognized as therapy; and we try to resolve this few-and-many paradox, identifying opportunities for better treatment, especially pre-diagnosis. The idea of dementia as a fate is resisted, we argue, because it negates the hope of a cure. But the price of that hope is lost opportunity. An approach more in line with the evidence, and more likely to limit suffering, is to understand the damage that accumulates with age in the cerebral vasculature and therefore in the brain, and which eventually gives rise to cognitive symptoms in late life, too often leading to dementia. We argue that hope should be redirected to delaying that damage and with it the onset of cognitive loss; and, for each individual, it should be redirected to a life-long defense of their brain.
Collapse
Affiliation(s)
- Marcus J Andersson
- Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia
| | - Jonathan Stone
- School of Medical Sciences and Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia
| |
Collapse
|
5
|
Ferrari-Díaz M, Bravo-Chávez RI, Silva-Pereyra J, Fernández T, García-Peña C, Rodríguez-Camacho M. Verbal intelligence and leisure activities are associated with cognitive performance and resting-state electroencephalogram. Front Aging Neurosci 2022; 14:921518. [PMID: 36268192 PMCID: PMC9577299 DOI: 10.3389/fnagi.2022.921518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 09/06/2022] [Indexed: 11/30/2022] Open
Abstract
Cognitive reserve (CR) is the adaptability of cognitive processes that helps to explain differences in the susceptibility of cognitive or daily functions to resist the onslaught of brain-related injury or the normal aging process. The underlying brain mechanisms of CR studied through electroencephalogram (EEG) are scarcely reported. To our knowledge, few studies have considered a combination of exclusively dynamic proxy measures of CR. We evaluated the association of CR with cognition and resting-state EEG in older adults using three of the most frequently used dynamic proxy measures of CR: verbal intelligence, leisure activities, and physical activities. Multiple linear regression analyses with the CR proxies as independent variables and cognitive performance and the absolute power (AP) on six resting-state EEG components (beta, alpha1, alpha2, gamma, theta, and delta) as outcomes were performed. Eighty-eight healthy older adults aged 60–77 (58 female) were selected from previous study data. Verbal intelligence was a significant positive predictor of perceptual organization, working memory, processing speed, executive functions, and central delta power. Leisure activities were a significant positive predictor of posterior alpha2 power. The dynamic proxy variables of CR are differently associated with cognitive performance and resting-state EEG. Implementing leisure activities and tasks to increase vocabulary may promote better cognitive performance through compensation or neural efficiency mechanisms.
Collapse
Affiliation(s)
- Martina Ferrari-Díaz
- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Mexico
| | - Ricardo Iván Bravo-Chávez
- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Mexico
| | - Juan Silva-Pereyra
- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Mexico
- *Correspondence: Juan Silva-Pereyra,
| | - Thalía Fernández
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Juriquilla, Mexico
| | - Carmen García-Peña
- Departamento de Investigación, Instituto Nacional de Geriatría, Ciudad de México, Mexico
| | - Mario Rodríguez-Camacho
- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, Mexico
| |
Collapse
|
6
|
Montine TJ, Corrada MM, Kawas C, Bukhari SA, White LR, Tian L, Cholerton B. Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest Old. Neurology 2022; 99:e1067-e1078. [PMID: 35705500 PMCID: PMC9519247 DOI: 10.1212/wnl.0000000000200832] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 04/22/2022] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Age is the largest risk factor for dementia. However, dementia is not universal, even among the oldest-old age groups. Following contemporary neuropathologic guidelines, our objectives were to describe the key neuropathologic lesions and their associations with antemortem cognition in oldest-old individuals. METHODS Participants were those enrolled in The 90+ Study, a longitudinal, population-based study of aging/dementia in the oldest old, who agreed to postmortem brain examination. All autopsied brains as of December 2020 were evaluated for the prevalence of Alzheimer disease neuropathologic change (ADNC) and non-ADNC neuropathologic comorbidities. Associations between neuropathologic lesions or the total neuropathologic burden score (sum of the individual scores) and cognition were assessed using multinomial logistic regression and multiple linear regression. Separate regression analyses evaluated relationships between limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) and hippocampal sclerosis (HS) or ADNC/primary age-related tauopathy (PART). Resistance, or failure to develop ADNC/PART, and resilience, inferred from higher-than-expected cognitive functioning, were evaluated in the presence or absence of non-ADNC neuropathologic features. RESULTS The most common neuropathologic features in the sample (n = 367) were ADNC/PART related. Increased dementia odds were associated with elevated total neuropathologic burden (odds ratio [OR] 1.5, 95% CI 1.3-1.7, p < 0.0001), β-amyloid (OR 1.6, 95% CI 1.2-2.0, p < 0.0001), neurofibrillary tangles (OR 2.6, 95% CI 1.7-4.1, p < 0.0001), and LATE-NC (OR 2.3, 95% CI 1.7-3.1, p < 0.0001), correcting for multiple comparisons. LATE-NC was associated with dementia with (OR 6.1, 95% CI 2.0-18.7, p = 0.002) and without (OR 5.0, 95% CI 2.6-9.7, p < 0.0001) co-occurring HS and increased the odds of dementia among participants with ADNC (OR 5.0, 95% CI 2.7-9.2, p < 0.0001). Resistance to moderate/severe ADNC/PART was rare (3%), but resilience to ADNC/PART was not (55%). Resilience was rarer in the presence of non-ADNC comorbid lesions, particularly LATE-NC. Among those with moderate/severe ADNC/PART, dementia odds increased with each non-ADNC comorbid lesion (e.g., 1 lesion: OR 2.4, 95% CI 1.3-4.5, p < 0.005; 2 lesions: OR 5.9, 95% CI 2.8-12.3, p < 0.0001). DISCUSSION These results highlight the importance of non-ADNC neuropathologic comorbidity, predominantly LATE-NC, to cognition in the oldest old. Given the cumulative effects of non-ADNC comorbid neuropathologic abnormalities, reducing their prevalence, especially LATE-NC, will be vital to the ultimate goal of reducing dementia burden in the oldest-old individuals.
Collapse
Affiliation(s)
- Thomas J Montine
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA
| | - Maria M Corrada
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA
| | - Claudia Kawas
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA
| | - Syed A Bukhari
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA
| | - Lon R White
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA
| | - Lu Tian
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA
| | - Brenna Cholerton
- From the Department of Pathology (T.J.M., S.B., B.C.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (M.M.C., C.K.), Epidemiology (M.M.C.), and Neurobiology & Behavior (C.K.), University of California Irvine; Pacific Health Research and Education Institute (L.W.), Honolulu, HI; and Department of Biomedical Data Science (L.T.), Stanford University School of Medicine, Palo Alto, CA.
| |
Collapse
|
7
|
Gómez-Isla T, Frosch MP. Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. Nat Rev Neurol 2022; 18:323-332. [PMID: 35332316 PMCID: PMC10607925 DOI: 10.1038/s41582-022-00642-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/24/2022] [Indexed: 12/12/2022]
Abstract
Since the original description of amyloid-β plaques and tau tangles more than 100 years ago, these lesions have been considered the neuropathological hallmarks of Alzheimer disease (AD). The prevalence of plaques, tangles and dementia increases with age, and the lesions are considered to be causally related to the cognitive symptoms of AD. Current schemes for assessing AD lesion burden examine the distribution, abundance and characteristics of plaques and tangles at post mortem, yielding an estimate of the likelihood of cognitive impairment. Although this approach is highly predictive for most individuals, in some instances, a striking mismatch between lesions and symptoms can be observed. A small subset of individuals harbour a high burden of plaques and tangles at autopsy, which would be expected to have had devastating clinical consequences, but remain at their cognitive baseline, indicating 'resilience'. The study of these brains might provide the key to understanding the 'black box' between the accumulation of plaques and tangles and cognitive impairment, and show the way towards disease-modifying treatments for AD. In this Review, we begin by considering the heterogeneity of clinical manifestations associated with the presence of plaques and tangles, and then focus on insights derived from the rare yet informative individuals who display high amounts of amyloid and tau deposition in their brains (observed directly at autopsy) without manifesting dementia during life. The resilient response of these individuals to the gradual accumulation of plaques and tangles has potential implications for assessing an individual's risk of AD and for the development of interventions aimed at preserving cognition.
Collapse
Affiliation(s)
- Teresa Gómez-Isla
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
- Massachusetts Alzheimer's Disease Research Center, Boston, MA, USA.
| | - Matthew P Frosch
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- Massachusetts Alzheimer's Disease Research Center, Boston, MA, USA
- C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA, USA
| |
Collapse
|
8
|
Ayton S, Bush AI. β-amyloid: The known unknowns. Ageing Res Rev 2021; 65:101212. [PMID: 33188924 DOI: 10.1016/j.arr.2020.101212] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 11/04/2020] [Accepted: 11/06/2020] [Indexed: 12/11/2022]
Abstract
Alzheimer's disease (AD) stands out as a major disease without any form of preventative or disease modifying therapy. This is not for lack of trying. 33 phase 3 clinical trials of drugs targeting amyloid beta (Aβ) have failed to slow cognitive decline in AD. The field is at a cross-roads about whether to continue anti-Aβ therapy or more actively pursue alternative targets. With the burden of this disease to patients, families, and healthcare budgets growing yearly, the need for disease modifying AD therapies has become one of the highest priorities in all of medicine. While pathology, genetic and biochemical data offer a popular narrative for the causative role of Aβ, there are alternative explanations, and dissenting findings that, now more than ever, warrant thorough reanalysis. This review questions the major assumptions about Aβ on which therapies for AD were premised, and invites renewed interrogation into AD pathogenesis.
Collapse
Affiliation(s)
- Scott Ayton
- Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, 3052, Australia.
| | - Ashley I Bush
- Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, 3052, Australia.
| |
Collapse
|
9
|
Castellani RJ. The Significance of Tau Aggregates in the Human Brain. Brain Sci 2020; 10:brainsci10120972. [PMID: 33322544 PMCID: PMC7763851 DOI: 10.3390/brainsci10120972] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2020] [Revised: 12/04/2020] [Accepted: 12/07/2020] [Indexed: 12/16/2022] Open
Abstract
Neurofibrillary degeneration has attracted the attention of neuroscientists as both a hallmark of the disease and a subject for experimentation for more than a century. Recent studies implicate phosphorylated tau (p-tau) directly in neurodegenerative disease pathogenesis, although the human data continue to raise questions. P-tau accumulates with age in a roughly hierarchical manner, but avoids abundance in the neocortex unless co-occurring with amyloid-β. Neurodegenerative tauopathies tend to have p-tau morphologies that differ from aging and Alzheimer’s disease. Tau isoforms (3R vs. 4R) have a tendency to vary with tauopathy phenotype for unknown reasons. Selective vulnerability to p-tau and spatial-temporal disconnect from amyloid-β are evident in aging. P-tau assessment at autopsy involves tissue decomposition, which may skew microanatomical observations toward limited biological meaning. Two major consensus guidelines for interpreting p-tau at autopsy emphasize the challenges of clinicopathologic correlation, and reinforce the observation that regional neurodegeneration is a better correlate of clinical signs than is proteinopathy. Despite the proliferation of interesting and novel theories related to tau-mediated pathogenesis, the weight of the human observations suggests that neurofibrillary degeneration is an epiphenomenal hallmark of aging and disease rather than an epicenter of neurotoxicity. This is consistent with numerous tau-targeted therapeutic strategies that have been unsuccessful to date.
Collapse
Affiliation(s)
- Rudy J. Castellani
- Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University, Morgantown, WV 26506, USA;
- Department of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA
| |
Collapse
|
10
|
Aiello Bowles EJ, Crane PK, Walker RL, Chubak J, LaCroix AZ, Anderson ML, Rosenberg D, Keene CD, Larson EB. Cognitive Resilience to Alzheimer's Disease Pathology in the Human Brain. J Alzheimers Dis 2020; 68:1071-1083. [PMID: 30909217 DOI: 10.3233/jad-180942] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Past research has focused on risk factors for developing dementia, with increasing recognition of "resilient" people who live to old age with intact cognitive function despite pathological features of Alzheimer's disease (AD). OBJECTIVE To evaluate demographic factors, mid-life characteristics, and non-AD neuropathology findings that may be associated with cognitive resilience to AD pathology. METHODS We analyzed data from 276 autopsy cases with intermediate or high levels of AD pathology from the Adult Changes in Thought study. We defined cognitive resilience as having Cognitive Abilities Screening Instrument scores ≥86 within two years of death and no clinical dementia diagnosis; non-resilient people had dementia diagnoses from AD or other causes before death. We compared mid-life characteristics, demographics, and additional neuropathology findings between resilient and non-resilient people. We used multivariable logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for being resilient compared to not being resilient adjusting for demographic and neuropathology factors. RESULTS We classified 68 (25%) people as resilient and 208 (75%) as not resilient. A greater proportion of resilient people had a college degree (50%) compared with non-resilient (32%, p = 0.01). The odds of being resilient were significantly increased among people with a college education (OR = 2.01, 95% CI = 1.01-3.99) and significantly reduced among people with additional non-AD neuropathology findings such as hippocampal sclerosis (OR = 0.28, 95% CI = 0.09-0.89) and microinfarcts (OR = 0.34, 95% CI = 0.15-0.78). CONCLUSION Increased education and absence of non-AD pathology may be independently associated with cognitive resilience, highlighting the importance of evaluating co-morbid factors in future research on mechanisms of cognitive resilience.
Collapse
Affiliation(s)
- Erin J Aiello Bowles
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA
| | - Paul K Crane
- Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, WA, USA
| | - Rod L Walker
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA
| | - Jessica Chubak
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.,Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Andrea Z LaCroix
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.,Department of Family Medicine and Public Health, Division of Epidemiology, University of California San Diego, La Jolla, CA, USA
| | - Melissa L Anderson
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA
| | - Dori Rosenberg
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA
| | - C Dirk Keene
- Department of Pathology, University of Washington, Seattle, WA, USA
| | - Eric B Larson
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.,Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, WA, USA
| |
Collapse
|
11
|
Li M, Reisman J, Morris-Eppolito B, Qian SX, Kazis LE, Wolozin B, Goldstein LE, Xia W. Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury. ALZHEIMERS RESEARCH & THERAPY 2020; 12:33. [PMID: 32220235 PMCID: PMC7102441 DOI: 10.1186/s13195-020-00589-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 02/25/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND Pathological analysis of brain tissue from animals and humans with a history of traumatic brain injury (TBI) suggests that TBI could be one of the risk factors facilitating onset of dementia with possible Alzheimer's disease (AD), but medications to prevent or delay AD onset are not yet available. METHODS This study explores four medication classes (angiotensin-converting enzyme inhibitors (ACEI), beta blockers, metformin, and statins) approved by the Food and Drug Administration (FDA) for other indications and evaluates their influence when used in combination on the risk of possible AD development for patients with a history of TBI. We identified patients with history of TBI from an existing Department of Veterans Affairs (VA) national database. Among 1,660,151 veterans who used VA services between the ages of 50 to 89 years old, we analyzed 733,920 patients, including 15,450 patients with a history of TBI and 718,470 non-TBI patients. The TBI patients were followed for up to 18.5 years, with an average of 7.7 ± 4.7 years, and onset of dementia with possible AD was recorded based on International Statistical Classification of Diseases (ICD) 9 or 10 codes. The effect of TBI on possible AD development was evaluated by multivariable logistic regression models adjusted by age, gender, race, and other comorbidities. The association of ACEI, beta blockers, metformin, statins, and combinations of these agents over time from the first occurrence of TBI to possible AD onset was assessed using Cox proportional hazard models adjusted for demographics and comorbidities. RESULTS Veterans with at least two TBI occurrences by claims data were 25% (odds ratio (OR) = 1.25, 95% confidence intervals (CI) (1.13, 1.37)) more likely to develop dementia with possible AD, compared to those with no record of TBI. In multivariable logistic regression models (propensity score weighted or adjusted), veterans taking a combination of ACEI and statins had reduced risk in developing possible AD after suffering TBI, and use of this medication class combination was associated with a longer period between TBI occurring and dementia with possible AD onset, compared to patients who took statins alone or did not take any of the four target drugs after TBI. CONCLUSIONS The combination of ACEI and statins significantly lowered the risk of development of dementia with possible AD in a national cohort of people with a history of TBI, thus supporting a clinical approach to lowering the risk of dementia with possible AD.
Collapse
Affiliation(s)
- Mingfei Li
- Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.,Department of Mathematical Sciences, Bentley University, Waltham, MA, USA
| | - Joel Reisman
- Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA
| | - Benjamin Morris-Eppolito
- Geriatric Research Education Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, 01730, USA
| | - Shirley X Qian
- Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.,Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, MA, USA
| | - Lewis E Kazis
- Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.,Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, MA, USA
| | - Benjamin Wolozin
- Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA
| | - Lee E Goldstein
- Departments of Radiology, Psychiatry, Neurology, and Pathology, Boston University School of Medicine, Boston, MA, USA.,Departments of Biomedical, Electrical, and Computer Engineering, Boston University College of Engineering & Photonics Center, Boston, MA, USA.,Boston University Alzheimer's Disease Center, Boston, MA, USA
| | - Weiming Xia
- Geriatric Research Education Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, 01730, USA. .,Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
| |
Collapse
|
12
|
Dumurgier J, Tzourio C. Epidemiology of neurological diseases in older adults. Rev Neurol (Paris) 2020; 176:642-648. [PMID: 32145981 DOI: 10.1016/j.neurol.2020.01.356] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 12/20/2019] [Accepted: 01/28/2020] [Indexed: 02/07/2023]
Abstract
Neurological diseases refer to the diseases that target the nervous system (brain, spine or nerves). They are the second leading cause of death, and the first cause of severe long-term disability in the world. The prevalence of most neurological diseases increases sharply with age, and age also modulates the impact of risk factors, clinical presentation and the natural course of these diseases. Longitudinal population-based studies provide useful insights for a better understanding of the specificities of neurological diseases in older adults by assessment of a wide range of risk factors. Rapid population aging, especially in low-income countries, presents challenges in terms of health and social care. A multidisciplinary approach is necessary to find solutions to tackle the burden of neurological diseases in older adults.
Collapse
Affiliation(s)
- J Dumurgier
- Cognitive Neurology Center, Saint-Louis - Lariboisière - Fernand-Widal Hospital, AP-HP, université de Paris, Paris, France; Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, université de Paris, Paris, France.
| | - C Tzourio
- Bordeaux Population Health Research Center, UMR1219, université de Bordeaux, Bordeaux, France
| |
Collapse
|
13
|
A third of community-dwelling elderly with intermediate and high level of Alzheimer's neuropathologic changes are not demented: A meta-analysis. Ageing Res Rev 2020; 58:101002. [PMID: 31899366 DOI: 10.1016/j.arr.2019.101002] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 12/18/2019] [Accepted: 12/20/2019] [Indexed: 01/13/2023]
Abstract
This systematic review and meta-analysis assessed the bidirectional association between AD pathology and dementia in community-dwelling elderly populations. We searched PubMed/MEDLINE, Embase, Scopus, Web of Science, and references of the pertinent articles for community/population-based longitudinal cohorts with regular assessment of cognitive status of participants followed by postmortem neuropathology data, with no language and date restrictions, until 20 September 2019. Finally, we retrieved 18 articles with data from 17 cohorts comprising 4677 persons. Dementia was twice as likely in participants with definitive neuropathological indicator for AD compared to those without it: moderate/high Braak and Braak (BB) stages III-VI of neurofibrillary tangles (54 % vs. 26 % in participants with BB stages 0-II), the Consortium to Establish a Registry for AD (CERAD) moderate/frequent neuritic plaques scores (64 % vs. 33 % in participants with CERAD none/infrequent), and National Institute on Aging and the Reagan Institute of the Alzheimer's Association criteria intermediate/high AD probability (52 % vs. 28 % in participants with no/low AD probability). Accordingly, a substantial proportion of community-dwelling elderly people with definitive AD pathology may not develop dementia. Brain reserve or contribution of other factors and pathologies, such as vascular and degenerative pathology to dementia might explain this apparent discrepancy. These findings also suggest caution in equating Alzheimer pathology biomarkers with dementia.
Collapse
|
14
|
Etter G, van der Veldt S, Manseau F, Zarrinkoub I, Trillaud-Doppia E, Williams S. Optogenetic gamma stimulation rescues memory impairments in an Alzheimer's disease mouse model. Nat Commun 2019; 10:5322. [PMID: 31757962 PMCID: PMC6876640 DOI: 10.1038/s41467-019-13260-9] [Citation(s) in RCA: 132] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 10/30/2019] [Indexed: 01/08/2023] Open
Abstract
Slow gamma oscillations (30-60 Hz) correlate with retrieval of spatial memory. Altered slow gamma oscillations have been observed in Alzheimer's disease. Here, we use the J20-APP AD mouse model that displays spatial memory loss as well as reduced slow gamma amplitude and phase-amplitude coupling to theta oscillations phase. To restore gamma oscillations in the hippocampus, we used optogenetics to activate medial septal parvalbumin neurons at different frequencies. We show that optogenetic stimulation of parvalbumin neurons at 40 Hz (but not 80 Hz) restores hippocampal slow gamma oscillations amplitude, and phase-amplitude coupling of the J20 AD mouse model. Restoration of slow gamma oscillations during retrieval rescued spatial memory in mice despite significant plaque deposition. These results support the role of slow gamma oscillations in memory and suggest that optogenetic stimulation of medial septal parvalbumin neurons at 40 Hz could provide a novel strategy for treating memory deficits in AD.
Collapse
Affiliation(s)
- Guillaume Etter
- McGill University & Douglas Mental Health University Institute, Montreal, Canada
| | | | - Frédéric Manseau
- McGill University & Douglas Mental Health University Institute, Montreal, Canada
| | - Iman Zarrinkoub
- McGill University & Douglas Mental Health University Institute, Montreal, Canada
| | | | - Sylvain Williams
- McGill University & Douglas Mental Health University Institute, Montreal, Canada.
| |
Collapse
|
15
|
The molecular lifecycle of amyloid – Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2019; 1867:140257. [DOI: 10.1016/j.bbapap.2019.07.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Revised: 07/12/2019] [Accepted: 07/23/2019] [Indexed: 12/11/2022]
|
16
|
Vico Varela E, Etter G, Williams S. Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. Neurobiol Dis 2019; 127:605-615. [DOI: 10.1016/j.nbd.2019.04.010] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 04/08/2019] [Accepted: 04/12/2019] [Indexed: 11/29/2022] Open
|
17
|
Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE, Henriksen J, Darvas M, Domoto-Reilly K, Jayadev S, Grabowski TJ, Crane PK, Larson EB, Kraemer BC, Bird TD, Keene CD. Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun 2019; 7:91. [PMID: 31174609 PMCID: PMC6556006 DOI: 10.1186/s40478-019-0743-1] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 05/16/2019] [Indexed: 02/07/2023] Open
Abstract
Alzheimer's disease neuropathologic change (ADNC) is defined by progressive accumulation of β-amyloid plaques and hyperphosphorylated tau (pTau) neurofibrillary tangles across diverse regions of brain. Non-demented individuals who reach advanced age without significant ADNC are considered to be resistant to AD, while those burdened with ADNC are considered to be resilient. Understanding mechanisms underlying ADNC resistance and resilience may provide important clues to treating and/or preventing AD associated dementia. ADNC criteria for resistance and resilience are not well-defined, so we developed stringent pathologic cutoffs for non-demented subjects to eliminate cases of borderline pathology. We identified 14 resistant (85+ years old, non-demented, Braak stage ≤ III, CERAD absent) and 7 resilient (non-demented, Braak stage VI, CERAD frequent) individuals out of 684 autopsies from the Adult Changes in Thought study, a long-standing community-based cohort. We matched each resistant or resilient subject to a subject with dementia and severe ADNC (Braak stage VI, CERAD frequent) by age, sex, year of death, and post-mortem interval. We expanded the neuropathologic evaluation to include quantitative approaches to assess neuropathology and found that resilient participants had lower neocortical pTau burden despite fulfilling criteria for Braak stage VI. Moreover, limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) was robustly associated with clinical dementia and was more prevalent in cases with high pTau burden, supporting the notion that resilience to ADNC may depend, in part, on resistance to pTDP-43 pathology. To probe for interactions between tau and TDP-43, we developed a C. elegans model of combined human (h) Tau and TDP-43 proteotoxicity, which exhibited a severe degenerative phenotype most compatible with a synergistic, rather than simply additive, interaction between hTau and hTDP-43 neurodegeneration. Pathways that underlie this synergy may present novel therapeutic targets for the prevention and treatment of AD.
Collapse
Affiliation(s)
- Caitlin S Latimer
- Division of Neuropathology, Department of Pathology, University of Washington, Seattle, WA, 98104, USA.
| | - Bridget T Burke
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Nicole F Liachko
- Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
- Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Heather N Currey
- Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
| | - Mitchell D Kilgore
- Division of Neuropathology, Department of Pathology, University of Washington, Seattle, WA, 98104, USA
| | - Laura E Gibbons
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Jonathan Henriksen
- Division of Neuropathology, Department of Pathology, University of Washington, Seattle, WA, 98104, USA
| | - Martin Darvas
- Division of Neuropathology, Department of Pathology, University of Washington, Seattle, WA, 98104, USA
| | | | - Suman Jayadev
- Department of Neurology, University of Washington, Seattle, Washington, USA
| | - Tom J Grabowski
- Department of Neurology, University of Washington, Seattle, Washington, USA
- Deparment of Radiology, University of Washington, Seattle, Washington, USA
| | - Paul K Crane
- Department of Medicine, University of Washington, Seattle, WA, USA
| | - Eric B Larson
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Brian C Kraemer
- Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
- Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
| | - Thomas D Bird
- Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
- Department of Neurology, University of Washington, Seattle, Washington, USA
- Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA, USA
| | - C Dirk Keene
- Division of Neuropathology, Department of Pathology, University of Washington, Seattle, WA, 98104, USA
| |
Collapse
|
18
|
Selvackadunco S, Langford K, Shah Z, Hurley S, Bodi I, King A, Aarsland D, Troakes C, Al-Sarraj S. Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. J Neural Transm (Vienna) 2019; 126:327-337. [PMID: 30730007 PMCID: PMC6449484 DOI: 10.1007/s00702-018-01967-w] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Accepted: 12/15/2018] [Indexed: 11/28/2022]
Abstract
Early detection and accurate diagnosis of neurodegenerative disorders may provide better epidemiological data, closer monitoring of disease progression and enable more specialised intervention. We analysed the clinical records and pathology of brain donations from 180 patients from two Brains for Dementia Research cohorts to determine the agreement between in-life clinical diagnosis and post-mortem pathological results. Clinical diagnosis was extracted from medical records and cases assigned into broad clinical groups; control, Alzheimer’s disease (AD), vascular dementia (CVD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and combined diseases. Pathology was assessed blindly, and cases categorised into; control, intermediate AD, severe AD, CVD, AD and CVD combined, DLB, AD and DLB combined and frontotemporal lobar degeneration (FTLD), according to the major contributing pathologies. In more than a third of cases clinical diagnosis was different from final neuropathological diagnosis. The majority of AD, DLB and control clinical groups matched the pathological diagnosis; however, thirty-five percent of clinical AD cases showed additional prominent CVD or DLB pathology which had not been diagnosed clinically and twenty-five percent of clinical control cases were found to have intermediate Tau pathology (modified Braak stage III–IV) or CVD. CVD and AD + CVD clinical groups showed an average of only thirty-two percent pathological correlation, the majority actually having no CVD, and fifty-three percent of pathologically identified FTLD cases had been incorrectly clinically diagnosed. Our results underlie the importance of neuropathological confirmation of clinical diagnosis. The relatively low accuracy of clinical diagnosis demonstrates the need for standardised and validated diagnostic assessment procedures.
Collapse
Affiliation(s)
- Sashika Selvackadunco
- Department of Basic and Clinical Neuroscience, IoPPN, King's College London, London, UK
| | - Katie Langford
- Old Age Psychiatry Department, IoPPN, King's College London, London, UK
| | - Zohra Shah
- Department of Basic and Clinical Neuroscience, IoPPN, King's College London, London, UK
| | - Siobhan Hurley
- Old Age Psychiatry Department, IoPPN, King's College London, London, UK
| | - Istvan Bodi
- Department of Basic and Clinical Neuroscience, IoPPN, King's College London, London, UK.,Department of Clinical Neuropathology, Academic Neuroscience Centre, King's College Hospital, King's College Hospital NHS Foundation Trust, 1st Floor, Denmark Hill, London, SE5 9RS, UK
| | - Andrew King
- Department of Basic and Clinical Neuroscience, IoPPN, King's College London, London, UK.,Department of Clinical Neuropathology, Academic Neuroscience Centre, King's College Hospital, King's College Hospital NHS Foundation Trust, 1st Floor, Denmark Hill, London, SE5 9RS, UK
| | - Dag Aarsland
- Old Age Psychiatry Department, IoPPN, King's College London, London, UK
| | - Claire Troakes
- Department of Basic and Clinical Neuroscience, IoPPN, King's College London, London, UK
| | - Safa Al-Sarraj
- Department of Basic and Clinical Neuroscience, IoPPN, King's College London, London, UK. .,Department of Clinical Neuropathology, Academic Neuroscience Centre, King's College Hospital, King's College Hospital NHS Foundation Trust, 1st Floor, Denmark Hill, London, SE5 9RS, UK.
| |
Collapse
|
19
|
Wennberg AM, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Machulda MM, Petrucelli L, Mielke MM, Jack CR, Knopman DS, Parisi JE, Petersen RC, Dickson DW, Josephs KA. The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiol Aging 2019; 77:26-36. [PMID: 30776649 DOI: 10.1016/j.neurobiolaging.2019.01.008] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 01/11/2019] [Accepted: 01/12/2019] [Indexed: 11/17/2022]
Abstract
Many individuals live to older ages without clinical impairment. It is unknown whether brain pathologies in these individuals are associated with subtle clinical deficits. We analyzed the brains of 161 clinically normal (Clinical Dementia Rating score = 0) older individuals enrolled in the Mayo Clinic Patient Registry or Study of Aging. We assessed for the presence and burden of beta-amyloid, tau, alpha-synuclein, TDP-43, and vascular pathology. We investigated whether pathologies were associated with antemortem cognitive and motor function, depression, MRI volumetric measures, or the apolipoprotein E (APOE) ε4 allele. Eighty-six percent had at least 1 pathology, and 63% had mixed pathologies. Tau and vascular pathology were associated with poorer memory scores. Tau was also associated with poorer general cognition scores and smaller amygdala, hippocampi, and entorhinal cortex volumes. Beta-amyloid neuritic plaque burden was associated with greater depression scores. The presence of a greater number of pathologies was associated with APOE e4 carrier status and with poorer memory performance. Some dementia-related pathologies are associated with poorer performance in clinical measures and brain atrophy in the unimpaired elderly.
Collapse
Affiliation(s)
| | | | | | - Stephen D Weigand
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | | | - Mary M Machulda
- Department of Psychology (Neuropsychiatry), Mayo Clinic, Rochester, MN, USA
| | | | - Michelle M Mielke
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | | | | | - Joseph E Parisi
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | | | - Dennis W Dickson
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | | |
Collapse
|
20
|
Reed MJ, Damodarasamy M, Pathan JL, Chan CK, Spiekerman C, Wight TN, Banks WA, Day AJ, Vernon RB, Keene CD. Increased Hyaluronan and TSG-6 in Association with Neuropathologic Changes of Alzheimer's Disease. J Alzheimers Dis 2019; 67:91-102. [PMID: 30507579 PMCID: PMC6398602 DOI: 10.3233/jad-180797] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Little is known about the extracellular matrix (ECM) during progression of AD pathology. Brain ECM is abundant in hyaluronan (HA), a non-sulfated glycosaminoglycan synthesized by HA synthases (HAS) 1-3 in a high molecular weight (MW) form that is degraded into lower MW fragments. We hypothesized that pathologic severity of AD is associated with increases in HA and HA-associated ECM molecules. To test this hypothesis, we assessed HA accumulation and size; HA synthases (HAS) 1-3; and the HA-stabilizing hyaladherin, TSG-6 in parietal cortex samples from autopsied research subjects with not AD (CERAD = 0, Braak = 0- II, n = 12-21), intermediate AD (CERAD = 2, Braak = III-IV, n = 13-18), and high AD (CERAD = 3, Braak = V-VI, n = 32-40) neuropathologic change. By histochemistry, HA was associated with deposits of amyloid and tau, and was also found diffusely in brain parenchyma, with overall HA quantity (measured by ELSA) significantly greater in brains with high AD neuropathology. Mean HA MW was similar among the samples. HAS2 and TSG-6 mRNA expression, and TSG-6 protein levels were significantly increased in high AD and both molecules were present in vasculature, NeuN-positive neurons, and Iba1-positive microglia. These results did not change when accounting for gender, advanced age (≥ 90 years versus <90 years), or the clinical diagnosis of dementia. Collectively, our results indicate a positive correlation between HA accumulation and AD neuropathology, and suggest a possible role for HA synthesis and metabolism in AD progression.
Collapse
Affiliation(s)
- MJ Reed
- Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA
| | - M Damodarasamy
- Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA
| | - JL Pathan
- Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA
| | - CK Chan
- Matrix Biology Program, Benaroya Research Institute, Virginia Mason, Seattle, WA, USA
| | - C Spiekerman
- Center for Biomedical Statistics, Institute for Translational Health Sciences, University of Washington, Seattle, WA, USA
| | - TN Wight
- Matrix Biology Program, Benaroya Research Institute, Virginia Mason, Seattle, WA, USA
| | - WA Banks
- Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA
- VA Puget Sound Health Care System, Geriatric Research Education and Clinical Center, Seattle, WA, USA
| | - AJ Day
- Wellcome Trust Centre for Cell-Matrix Research, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
| | - RB Vernon
- Matrix Biology Program, Benaroya Research Institute, Virginia Mason, Seattle, WA, USA
| | - CD Keene
- Department of Pathology, Division of Neuropathology, University of Washington, Seattle, WA, USA
| |
Collapse
|
21
|
Dolcetta D, Dominici R. The local mammalian target of rapamycin (mTOR) modulation: a promising strategy to counteract neurodegeneration. Neural Regen Res 2019; 14:1711-1712. [PMID: 31169184 PMCID: PMC6585559 DOI: 10.4103/1673-5374.257524] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
| | - Roberto Dominici
- Clinical Chemistry Laboratory, Magenta Hospital, ASST Ovest Milanese, Milan, Italy
| |
Collapse
|
22
|
Abstract
Exceptional longevity represents an extreme phenotype. Current centenarians are survivors of a cohort who display delayed onset of age-related diseases and/or resistance to otherwise lethal illnesses occurring earlier in life. Characteristics of aging are heterogeneous, even among long-lived individuals. Associations between specific clinical or genetic biomarkers exist, but there is unlikely to be a single biomarker predictive of long life. Careful observations in the oldest old offer some empirical strategies that favor increased health span and life span, with implications for compression of disability, identification and implementation of lifestyle behaviors that promote independence, identification and measurement of more reliable markers associated with longevity, better guidance for appropriate health screenings, and promotion of anticipatory health discussions in the setting of more accurate prognostication. Comprehensive PubMed literature searches were performed, with an unbiased focus on mechanisms of longevity. Overall, the aggregate literature supports that the basis for exceptional longevity is multifactorial and involves disparate combinations of genes, environment, resiliency, and chance, all of which are influenced by culture and geography.
Collapse
Affiliation(s)
- Robert J Pignolo
- Division of Geriatric Medicine and Gerontology, Mayo Clinic, Rochester, MN.
| |
Collapse
|
23
|
Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathol 2018; 136:663-689. [PMID: 30349969 PMCID: PMC6208728 DOI: 10.1007/s00401-018-1918-8] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 09/28/2018] [Accepted: 09/30/2018] [Indexed: 12/29/2022]
Abstract
The dominant hypothesis of Alzheimer’s disease (AD) aetiology, the neuropathological guidelines for diagnosing AD and the majority of high-profile therapeutic efforts, in both research and in clinical practice, have been built around one possible causal factor, amyloid-β (Aβ). However, the causal link between Aβ and AD remains unproven. Here, in the context of a detailed assessment of historical and contemporary studies, we raise critical questions regarding the role of Aβ in the definition, diagnosis and aetiology of AD. We illustrate that a holistic view of the available data does not support an unequivocal conclusion that Aβ has a central or unique role in AD. Instead, the data suggest alternative views of AD aetiology are potentially valid, at this time. We propose that an unbiased way forward for the field, beyond the current Aβ-centric approach, without excluding a role for Aβ, is required to come to an accurate understanding of AD dementia and, ultimately, an effective treatment.
Collapse
|
24
|
Morgello S, Jacobs M, Murray J, Byrd D, Neibart E, Mintz L, Meloni G, Chon C, Crary J. Alzheimer's disease neuropathology may not predict functional impairment in HIV: a report of two individuals. J Neurovirol 2018; 24:629-637. [PMID: 30094630 DOI: 10.1007/s13365-018-0663-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 06/23/2018] [Accepted: 07/03/2018] [Indexed: 01/27/2023]
Abstract
With aging of HIV populations, there is concern that Alzheimer's disease (AD) may become prevalent and difficult to distinguish from HIV-associated neurocognitive disorders. To date, there are no reports documenting histologically verified Alzheimer's neuropathology in individuals with HIV and dementia. Herein, we report two antiretroviral-treated, virally suppressed, HIV-infected individuals autopsied by the Manhattan HIV Brain Bank. Subject A presented to study at 52 years, already dependent in instrumental activities of daily living (ADLs), with severe cognitive impairment inclusive of learning and memory dysfunction. Her history was significant for educational disability and head trauma. She had rapid cognitive decline and, by death at age 59 years, was bed-bound, incontinent, and non-communicative. At autopsy, she exhibited severe AD neuropathologic change (NIA-AA score A3B3C3) and age-related tau astrogliopathy (ARTAG). She was homozygous for APOE ε3/ε3. No HIV DNA was detected in frontal lobe by nested polymerase chain reaction. Subject B was a community dwelling 81-year-old woman who experienced sudden death by pulmonary embolus. Prior to death, she was fully functional, living independently, and managing all ADLs. At autopsy, she displayed moderate amyloid and severe tau AD neuropathologic changes (A2B3C2), ARTAG, and cerebral congophilic angiopathy. She was an APOE ε3/ε4 heterozygote, and HIV DNA, but not RNA, was detected in frontal lobe, despite 20 years of therapy-induced viral suppression. We conclude that in the setting of HIV, AD neuropathology may occur with or without symptomatic cognitive dysfunction; as with seronegative individuals, there are likely to be complex factors in the generation of clinically relevant impairments.
Collapse
Affiliation(s)
- Susan Morgello
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA. .,Department of Neuroscience and Pathology, The Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
| | - Michelle Jacobs
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA
| | - Jacinta Murray
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA
| | - Desiree Byrd
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA.,Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
| | - Eric Neibart
- Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
| | - Letty Mintz
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA
| | - Gregory Meloni
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA
| | - Christina Chon
- Department of Neurology, The Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, Gustave L Levy Place, Box 1137, New York, NY, 10029, USA
| | - John Crary
- Department of Neuroscience and Pathology, The Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
| |
Collapse
|
25
|
Di Gregorio SE, Duennwald ML. Yeast as a model to study protein misfolding in aged cells. FEMS Yeast Res 2018; 18:4996350. [DOI: 10.1093/femsyr/foy054] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Accepted: 05/13/2018] [Indexed: 12/16/2022] Open
Affiliation(s)
- Sonja E Di Gregorio
- Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada
| | - Martin L Duennwald
- Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada
| |
Collapse
|
26
|
Abstract
Delirium is a common, often underdiagnosed, geriatric syndrome characterized by an acute change in attention and consciousness. As a neuropsychiatric disorder with an underlying organic cause, delirium has been considered a diagnosis reserved for the hospital setting. However, delirium is known to occur as both an acute and subacute condition that carries significant morbidity and mortality. Combined with its association with dementia and aging, this makes delirium an important topic for primary care providers to become more familiar with as they are tasked with caring for an aging population.
Collapse
|
27
|
Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 2018; 64:S161-S189. [PMID: 29865057 PMCID: PMC6380522 DOI: 10.3233/jad-179939] [Citation(s) in RCA: 681] [Impact Index Per Article: 113.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND The Religious Orders Study and Rush Memory and Aging Project are both ongoing longitudinal clinical-pathologic cohort studies of aging and Alzheimer's disease (AD). OBJECTIVES To summarize progress over the past five years and its implications for understanding neurodegenerative diseases. METHODS Participants in both studies are older adults who enroll without dementia and agree to detailed longitudinal clinical evaluations and organ donation. The last review summarized findings through the end of 2011. Here we summarize progress and study findings over the past five years and discuss new directions for how these studies can inform on aging and AD in the future. RESULTS We summarize 1) findings on the relation of neurobiology to clinical AD; 2) neurobiologic pathways linking risk factors to clinical AD; 3) non-cognitive AD phenotypes including motor function and decision making; 4) the development of a novel drug discovery platform. CONCLUSION Complexity at multiple levels needs to be understood and overcome to develop effective treatments and preventions for cognitive decline and AD dementia.
Collapse
Affiliation(s)
- David A. Bennett
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL., USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL., USA
| | - Aron S. Buchman
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL., USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL., USA
| | - Patricia A. Boyle
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL., USA
- Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL., USA
| | - Lisa L. Barnes
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL., USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL., USA
- Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL., USA
| | - Robert S. Wilson
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL., USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL., USA
- Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL., USA
| | - Julie A Schneider
- Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL., USA
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL., USA
- Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, IL., USA
| |
Collapse
|
28
|
Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care. Lancet 2017; 390:2673-2734. [PMID: 28735855 DOI: 10.1016/s0140-6736(17)31363-6] [Citation(s) in RCA: 3473] [Impact Index Per Article: 496.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 01/20/2017] [Accepted: 01/25/2017] [Indexed: 12/15/2022]
Affiliation(s)
- Gill Livingston
- Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.
| | | | - Vasiliki Orgeta
- Division of Psychiatry, University College London, London, UK
| | - Sergi G Costafreda
- Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK
| | - Jonathan Huntley
- Division of Psychiatry, University College London, London, UK; Department of Old Age Psychiatry, King's College London, London, UK
| | - David Ames
- National Ageing Research Institute, Parkville, VIC, Australia; Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, VIC, Australia
| | | | - Sube Banerjee
- Centre for Dementia Studies, Brighton and Sussex Medical School, University of Sussex, Brighton, UK
| | - Alistair Burns
- Centre for Dementia Studies, University of Manchester, Manchester, UK
| | - Jiska Cohen-Mansfield
- Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Heczeg Institute on Aging, Tel Aviv University, Tel Aviv, Israel; Minerva Center for Interdisciplinary Study of End of Life, Tel Aviv University, Tel Aviv, Israel
| | - Claudia Cooper
- Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK
| | - Nick Fox
- Dementia Research Centre, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
| | - Laura N Gitlin
- Center for Innovative Care in Aging, Johns Hopkins University, Baltimore, MD, USA
| | - Robert Howard
- Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK
| | - Helen C Kales
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA; VA Center for Clinical Management Research, Ann Arbor, MI, USA
| | - Eric B Larson
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA
| | - Karen Ritchie
- Inserm, Unit 1061, Neuropsychiatry: Epidemiological and Clinical Research, La Colombière Hospital, University of Montpellier, Montpellier, France; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Kenneth Rockwood
- Centre for the Health Care of Elderly People, Geriatric Medicine Dalhousie University, Halifax, NS, Canada
| | - Elizabeth L Sampson
- Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London, London, UK
| | - Quincy Samus
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview, Johns Hopkins University, Baltimore, MD, USA
| | - Lon S Schneider
- Department of Neurology and Department of Psychiatry and the Behavioural Sciences, Keck School of Medicine, Leonard Davis School of Gerontology of the University of Southern California, Los Angeles, CA, USA
| | - Geir Selbæk
- Norwegian National Advisory Unit on Aging and Health, Vestfold Health Trust, Tønsberg, Norway; Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway; Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway
| | - Linda Teri
- Department Psychosocial and Community Health, School of Nursing, University of Washington, Seattle, WA, USA
| | - Naaheed Mukadam
- Division of Psychiatry, University College London, London, UK
| |
Collapse
|
29
|
Zolochevska O, Taglialatela G. Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies. Curr Pharm Des 2017; 22:4063-8. [PMID: 27189599 DOI: 10.2174/1381612822666160518142110] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 05/17/2016] [Indexed: 11/22/2022]
Abstract
Alzheimer's disease (AD) is a terminal neurodegenerative disorder that is characterized by accumulation of amyloid plaques and neurofibrillary tangles in the central nervous system. However, certain individuals remain cognitively intact despite manifestation of substantial plaques and tangles consistent with what would be normally associated with fully symptomatic AD. Mechanisms that allow these subjects to escape dementia remain unresolved and understanding such protective biological processes could reveal novel targets for the development of effective treatments for AD. In this review article we discuss potential compensatory mechanisms that allow these individuals to remain cognitively intact despite the typical AD neuropathology.
Collapse
Affiliation(s)
- Olga Zolochevska
- Department of Neurology, University of Texas Medical Branch, Galveston, Texas, USA.
| | | |
Collapse
|
30
|
A general neurologist's perspective on the urgent need to apply resilience thinking to the prevention and treatment of Alzheimer's disease. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS 2017; 3:498-506. [PMID: 29124107 PMCID: PMC5671621 DOI: 10.1016/j.trci.2017.08.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The goal of this article was to look at the problem of Alzheimer's disease (AD) through the lens of a socioecological resilience-thinking framework to help expand our view of the prevention and treatment of AD. This serious and complex public health problem requires a holistic systems approach. We present the view that resilience thinking, a theoretical framework that offers multidisciplinary approaches in ecology and natural resource management to solve environmental problems, can be applied to the prevention and treatment of AD. Resilience thinking explains a natural process that occurs in all complex systems in response to stressful challenges. The brain is a complex system, much like an ecosystem, and AD is a disturbance (allostatic overload) within the ecosystem of the brain. Resilience thinking gives us guidance, direction, and ideas about how to comprehensively prevent and treat AD and tackle the AD epidemic.
Collapse
|
31
|
Latimer CS, Keene CD, Flanagan ME, Hemmy LS, Lim KO, White LR, Montine KS, Montine TJ. Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. J Neuropathol Exp Neurol 2017; 76:458-466. [PMID: 28499012 DOI: 10.1093/jnen/nlx030] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Two population-based studies key to advancing knowledge of brain aging are the Honolulu-Asia Aging Study (HAAS) and the Nun Study. Harmonization of their neuropathologic data allows cross comparison, with findings common to both studies likely generalizable, while distinct observations may point to aging brain changes that are dependent on sex, ethnicity, environment, or lifestyle factors. Here, we expanded the neuropathologic evaluation of these 2 studies using revised NIA-Alzheimer's Association guidelines and compared directly the neuropathologic features of resistance and apparent cognitive resilience. There were significant differences in prevalence of Alzheimer disease neuropathologic change, small vessel vascular brain injury, and Lewy body disease between these 2 studies, suggesting that sex, ethnicity, and lifestyle factors may significantly influence resistance to developing brain injury with age. In contrast, hippocampal sclerosis prevalence was very similar, but skewed to poorer cognitive performance, suggesting that hippocampal sclerosis could act sequentially with other diseases to impair cognitive function. Strikingly, despite these observed differences, the proportion of individuals resistant to all 4 diseases of brain or displaying apparent cognitive resilience was virtually identical between HAAS and Nun Study participants. Future in vivo validation of these results awaits comprehensive biomarkers of these 4 brain diseases.
Collapse
Affiliation(s)
- Caitlin S Latimer
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - C Dirk Keene
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - Margaret E Flanagan
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - Laura S Hemmy
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - Kelvin O Lim
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - Lon R White
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - Kathleen S Montine
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| | - Thomas J Montine
- From the Department of Pathology, University of Washington, Seattle, Washington (CSL, CDK); Department of Pathology, Stanford University, Stanford, California (MEF, KSM, TJM); Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota (LSH, KOL); Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, Minnesota (LSH); Pacific Health Research and Education Institute (PHREI), Honolulu, Hawaii (LRW); and Department of Geriatric Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii (LRW)
| |
Collapse
|
32
|
Condello C, Stöehr J. Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiol Dis 2017; 109:191-200. [PMID: 28359847 DOI: 10.1016/j.nbd.2017.03.014] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 03/09/2017] [Accepted: 03/26/2017] [Indexed: 12/13/2022] Open
Abstract
The progressive nature of Alzheimer's disease (AD) is thought to occur, at least in part, by the self-replication and spreading of Aβ and Tau aggregates through a prion mechanism. Evidence now exists that structural variants of Aβ prions can propagate their distinct conformations through template-directed folding of naïve Aβ peptides. This notion implicates that the first self-propagating Aβ assembly to emerge in the brain dictates the conformation, anatomical spread and pace of subsequently formed deposits. It is hypothesized that a prion mechanism defines the molecular basis underlying the diverse clinicopathologic phenotypes observed across the spectrum of AD patients. Thus, distinct AD strains might require further sub-classification based on biochemical and structural characterization of aggregated Aβ. Here, we review the evidence for distinct, self-propagating Aβ strains, and discuss potential cellular mechanisms that might contribute to their manifestation. From this perspective, we also explore the implications of Aβ strains for current FDA-approved medical imaging probes and therapies for amyloid. Ultimately, the discovery of new molecular tools to differentiate Aβ strains and dissect the heterogeneity of AD may lead to the development of more informative diagnostics and strain-specific therapeutics.
Collapse
Affiliation(s)
- Carlo Condello
- Institute for Neurodegenerative Diseases, Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, United States
| | - Jan Stöehr
- Institute for Neurodegenerative Diseases, Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, United States.
| |
Collapse
|
33
|
Ware C, Damnee S, Djabelkhir L, Cristancho V, Wu YH, Benovici J, Pino M, Rigaud AS. Maintaining Cognitive Functioning in Healthy Seniors with a Technology-Based Foreign Language Program: A Pilot Feasibility Study. Front Aging Neurosci 2017; 9:42. [PMID: 28298892 PMCID: PMC5331045 DOI: 10.3389/fnagi.2017.00042] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 02/16/2017] [Indexed: 11/23/2022] Open
Abstract
Researchers have hypothesized that learning a foreign language could be beneficial for seniors, as language learning requires the use of extensive neural networks. We developed and qualitatively evaluated an English training program for older French adults; our principal objective was to determine whether a program integrating technology is feasible for this population. We conducted a 4-month pilot study (16, 2-h sessions) with 14 French participants, (nine women, five men, average age 75). Questionnaires were administered pre- and post-intervention to measure cognitive level and subjective feelings of loneliness or social isolation; however, these scores did not improve significantly. Post-intervention, semi-directive interviews were carried out with participants, and a content/theme analysis was performed. Five main themes were identified from the interviews: Associations with school, attitudes toward English, motivation for learning English, attitudes toward the program’s organization, and social ties. The program was found to be feasible for this age group, yet perceived as quite difficult for participants who lacked experience with English. Nonetheless, most participants found the program to be stimulating and enjoyable. We discuss different suggestions for future programs and future directions for foreign-language learning as a therapeutic and cognitive intervention.
Collapse
Affiliation(s)
- Caitlin Ware
- Department of Psychoanalytical Studies, University of Paris VII Diderot Paris, France
| | - Souad Damnee
- Department of Clinical Gerontology, Broca Hospital Paris, France
| | - Leila Djabelkhir
- Department of Clinical Gerontology, Broca HospitalParis, France; Faculty of Medicine, University of Paris DescartesParis, France
| | - Victoria Cristancho
- Department of Clinical Gerontology, Broca HospitalParis, France; Faculty of Medicine, University of Paris DescartesParis, France
| | - Ya-Huei Wu
- Department of Clinical Gerontology, Broca HospitalParis, France; Faculty of Medicine, University of Paris DescartesParis, France
| | - Judith Benovici
- Faculty of Medicine, University of Paris Descartes Paris, France
| | - Maribel Pino
- Department of Clinical Gerontology, Broca HospitalParis, France; Faculty of Medicine, University of Paris DescartesParis, France
| | - Anne-Sophie Rigaud
- Department of Clinical Gerontology, Broca HospitalParis, France; Faculty of Medicine, University of Paris DescartesParis, France
| |
Collapse
|
34
|
Suemoto CK, Ferretti-Rebustini REL, Rodriguez RD, Leite REP, Soterio L, Brucki SMD, Spera RR, Cippiciani TM, Farfel JM, Chiavegatto Filho A, Naslavsky MS, Zatz M, Pasqualucci CA, Jacob-Filho W, Nitrini R, Grinberg LT. Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study. PLoS Med 2017; 14:e1002267. [PMID: 28350821 PMCID: PMC5369698 DOI: 10.1371/journal.pmed.1002267] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 02/15/2017] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Clinicopathological studies are important in determining the brain lesions underlying dementia. Although almost 60% of individuals with dementia live in developing countries, few clinicopathological studies focus on these individuals. We investigated the frequency of neurodegenerative and vascular-related neuropathological lesions in 1,092 Brazilian admixed older adults, their correlation with cognitive and neuropsychiatric symptoms, and the accuracy of dementia subtype diagnosis. METHODS AND FINDINGS In this cross-sectional study, we describe clinical and neuropathological variables related to cognitive impairment in 1,092 participants (mean age = 74 y, 49% male, 69% white, and mean education = 4 y). Cognitive function was investigated using the Clinical Dementia Rating (CDR) and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); neuropsychiatric symptoms were evaluated using the Neuropsychiatric Inventory (NPI). Associations between neuropathological lesions and cognitive impairment were investigated using ordinal logistic regression. We developed a neuropathological comorbidity (NPC) score and compared it to CDR, IQCODE, and NPI scores. We also described and compared the frequency of neuropathological diagnosis to clinical diagnosis of dementia subtype. Forty-four percent of the sample met criteria for neuropathological diagnosis. Among these participants, 50% had neuropathological diagnoses of Alzheimer disease (AD), and 35% of vascular dementia (VaD). Neurofibrillary tangles (NFTs), hippocampal sclerosis, lacunar infarcts, hyaline atherosclerosis, siderocalcinosis, and Lewy body disease were independently associated with cognitive impairment. Higher NPC scores were associated with worse scores in the CDR sum of boxes (β = 1.33, 95% CI 1.20-1.46), IQCODE (β = 0.14, 95% CI 0.13-0.16), and NPI (β = 1.74, 95% CI = 1.33-2.16). Compared to neuropathological diagnoses, clinical diagnosis had high sensitivity to AD and high specificity to dementia with Lewy body/Parkinson dementia. The major limitation of our study is the lack of clinical follow-up of participants during life. CONCLUSIONS NFT deposition, vascular lesions, and high NPC scorewere associated with cognitive impairment in a unique Brazilian sample with low education. Our results confirm the high prevalence of neuropathological diagnosis in older adults and the mismatch between clinical and neuropathological diagnoses.
Collapse
Affiliation(s)
- Claudia K. Suemoto
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Division of Geriatrics, University of São Paulo Medical School, São Paulo, Brazil
| | - Renata E. L. Ferretti-Rebustini
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Department of Medical Surgical Nursing, University of São Paulo Nursing School, São Paulo, Brazil
| | - Roberta D. Rodriguez
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil
| | - Renata E. P. Leite
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Division of Geriatrics, University of São Paulo Medical School, São Paulo, Brazil
| | - Luciana Soterio
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
| | - Sonia M. D. Brucki
- Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil
| | - Raphael R. Spera
- Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil
| | | | - Jose M. Farfel
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Division of Geriatrics, University of São Paulo Medical School, São Paulo, Brazil
| | | | - Michel Satya Naslavsky
- Human Genome and Stem Cell Center, Biosciences Institute, University of São Paulo, São Paulo, Brazil
| | - Mayana Zatz
- Human Genome and Stem Cell Center, Biosciences Institute, University of São Paulo, São Paulo, Brazil
| | - Carlos A. Pasqualucci
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil
| | - Wilson Jacob-Filho
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Division of Geriatrics, University of São Paulo Medical School, São Paulo, Brazil
| | - Ricardo Nitrini
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil
| | - Lea T. Grinberg
- Brazilian Aging Brain Study Group, University of São Paulo Medical School, São Paulo, Brazil
- Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil
- Memory and Aging Center, University of California San Francisco, San Francisco, California, United States of America
- * E-mail:
| |
Collapse
|
35
|
Szalárdy L, Zádori D, Klivényi P, Vécsei L. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis. J Alzheimers Dis 2016; 53:373-92. [DOI: 10.3233/jad-160037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Levente Szalárdy
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
| | - Dénes Zádori
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
| | - Péter Klivényi
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
| | - László Vécsei
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
- MTA-SZTE Neuroscience Research Group, Szeged, Hungary
| |
Collapse
|
36
|
Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA, Smith CD, Fardo DW, Wang WX, Kryscio RJ, Neltner JH, Kukull WA, Cykowski MD, Van Eldik LJ, Ighodaro ET. "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). J Neuropathol Exp Neurol 2016; 75:482-98. [PMID: 27209644 PMCID: PMC6366658 DOI: 10.1093/jnen/nlw033] [Citation(s) in RCA: 117] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Indexed: 12/12/2022] Open
Abstract
The pathology-based classification of Alzheimer's disease (AD) and other neurodegenerative diseases is a work in progress that is important for both clinicians and basic scientists. Analyses of large autopsy series, biomarker studies, and genomics analyses have provided important insights about AD and shed light on previously unrecognized conditions, enabling a deeper understanding of neurodegenerative diseases in general. After demonstrating the importance of correct disease classification for AD and primary age-related tauopathy, we emphasize the public health impact of an underappreciated AD "mimic," which has been termed "hippocampal sclerosis of aging" or "hippocampal sclerosis dementia." This pathology affects >20% of individuals older than 85 years and is strongly associated with cognitive impairment. In this review, we provide an overview of current hypotheses about how genetic risk factors (GRN, TMEM106B, ABCC9, and KCNMB2), and other pathogenetic influences contribute to TDP-43 pathology and hippocampal sclerosis. Because hippocampal sclerosis of aging affects the "oldest-old" with arteriolosclerosis and TDP-43 pathologies that extend well beyond the hippocampus, more appropriate terminology for this disease is required. We recommend "cerebral age-related TDP-43 and sclerosis" (CARTS). A detailed case report is presented, which includes neuroimaging and longitudinal neurocognitive data. Finally, we suggest a neuropathology-based diagnostic rubric for CARTS.
Collapse
Affiliation(s)
- Peter T Nelson
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC).
| | - John Q Trojanowski
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Erin L Abner
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Omar M Al-Janabi
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Gregory A Jicha
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Frederick A Schmitt
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Charles D Smith
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - David W Fardo
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Wang-Xia Wang
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Richard J Kryscio
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Janna H Neltner
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Walter A Kukull
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Matthew D Cykowski
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Linda J Van Eldik
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| | - Eseosa T Ighodaro
- From the Department of Pathology, Division of Neuropathology (PTN, JHN), Department of Neurology (GAJ, FAS, CDS), Department of Statistics (DWF, RJK), Department of Anatomy and Neurobiology (PTN, JHN, LJVE, ETI), Department of Epidemiology (ELA), and Sanders-Brown Center on Aging (PTN, ELA, OMA-J, GAJ, FAS, CDS, DWF, WXW, RJK, LJVE, ETI), University of Kentucky, Lexington, Kentucky; Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvannia (JQT); Department of Epidemiology, University of Washington, Seattle, Washington (WAK); and Department of Pathology, Houston Methodist Hospital, Houston, Texas (MDC)
| |
Collapse
|
37
|
Scheff SW, Ansari MA, Mufson EJ. Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiol Aging 2016; 42:1-12. [PMID: 27143416 DOI: 10.1016/j.neurobiolaging.2016.02.030] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Revised: 02/26/2016] [Accepted: 02/28/2016] [Indexed: 12/11/2022]
Abstract
Neuritic amyloid plaques and neurofibrillary tangles are hallmarks of Alzheimer's disease (AD) and are major components used for the clinical diagnosis of this disorder. However, many individuals with no cognitive impairment (NCI) also present at autopsy with high levels of these AD pathologic hallmarks. In this study, we evaluated 15 autopsy cases from NCI individuals with high levels of AD-like pathology (high pathology no cognitive impairment) and compared them to age- and postmortem-matched cohorts of individuals with amnestic mild cognitive impairment and NCI cases with low AD-like pathology (low pathology no cognitive impairment [LPNCI]). Individuals classified as high pathology no cognitive impairment or amnestic mild cognitive impairment had a significant loss of both presynaptic and postsynaptic proteins in the hippocampus compared with those in the LPNCI cohort. In addition, these 2 groups had a significant increase in 3 different markers of oxidative stress compared with that in the LPNCI group. The changes in levels of synaptic proteins are strongly associated with levels of oxidative stress. These data suggest that cognitively older subjects without dementia but with increased levels of AD-like pathology may represent a very early preclinical stage of AD.
Collapse
Affiliation(s)
- Stephen W Scheff
- Department of Anatomy and Neurobiology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
| | - Mubeen A Ansari
- Department of Anatomy and Neurobiology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - Elliott J Mufson
- Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA
| |
Collapse
|
38
|
White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, Uyehara-Lock JH, Gelber RP, Ross GW, Petrovitch H, Masaki KH, Lim KO, Launer LJ, Montine TJ. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology 2016; 86:1000-8. [PMID: 26888993 DOI: 10.1212/wnl.0000000000002480] [Citation(s) in RCA: 127] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 12/01/2015] [Indexed: 01/13/2023] Open
Abstract
OBJECTIVE To examine frequencies and relationships of 5 common neuropathologic abnormalities identified at autopsy with late-life cognitive impairment and dementia in 2 different autopsy panels. METHODS The Nun Study (NS) and the Honolulu-Asia Aging Study (HAAS) are population-based investigations of brain aging that included repeated cognitive assessments and comprehensive brain autopsies. The neuropathologic abnormalities assessed were Alzheimer disease (AD) neuropathologic changes, neocortical Lewy bodies (LBs), hippocampal sclerosis, microinfarcts, and low brain weight. Associations with screening tests for cognitive impairment were examined. RESULTS Neuropathologic abnormalities occurred at levels ranging from 9.7% to 43%, and were independently associated with cognitive impairment in both studies. Neocortical LBs and AD changes were more frequent among the predominantly Caucasian NS women, while microinfarcts were more common in the Japanese American HAAS men. Comorbidity was usual and very strongly associated with cognitive impairment. Apparent cognitive resilience (no cognitive impairment despite Braak stage V) was strongly associated with minimal or no comorbid abnormalities, with fewer neocortical AD lesions, and weakly with longer interval between final testing and autopsy. CONCLUSIONS Total burden of comorbid neuropathologic abnormalities, rather than any single lesion type, was the most relevant determinant of cognitive impairment in both cohorts, often despite clinical diagnosis of only AD. These findings emphasize challenges to dementia pathogenesis and intervention research and to accurate diagnoses during life.
Collapse
Affiliation(s)
- Lon R White
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI.
| | - Steven D Edland
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Laura S Hemmy
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Kathleen S Montine
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Chris Zarow
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Joshua A Sonnen
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Jane H Uyehara-Lock
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Rebecca P Gelber
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - G Webster Ross
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Helen Petrovitch
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Kamal H Masaki
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Kelvin O Lim
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Lenore J Launer
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| | - Thomas J Montine
- From the Pacific Health Research and Education Institute (L.R.W., R.P.G., G.W.R., H.P.); Departments of Geriatric Medicine (L.R.W., H.P., K.H.M.), Pathology (J.H.U.-L.), and Medicine (G.W.R., H.P.), University of Hawaii John A. Burns School of Medicine, Honolulu; Laboratory of Epidemiology and Population Sciences Intramural Research Program (L.R.W., L.J.L.), National Institute on Aging, NIH, Bethesda, MD; Departments of Family Preventive Medicine (S.D.E.) and Neurosciences (S.D.E.), University of California San Diego, La Jolla; Department of Psychiatry (L.S.H., K.O.L.), University of Minnesota, Minneapolis; Geriatric Research, Education, and Clinical Center (L.R.W., L.S.H., K.O.L.), VA Medical Center, Minneapolis, MN; Department of Pathology (K.S.M., T.J.M.), University of Washington, Seattle; Department of Neurology (C.Z.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Pathology (J.A.S.), University of Utah, Salt Lake City; VA Pacific Islands Health Care System (R.P.G., G.W.R., H.P.); and Kuakini Medical Center (K.H.M.), Honolulu, HI
| |
Collapse
|
39
|
The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016; 36:172-86. [PMID: 26174330 PMCID: PMC4758551 DOI: 10.1038/jcbfm.2015.164] [Citation(s) in RCA: 258] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 06/12/2015] [Accepted: 06/15/2015] [Indexed: 12/23/2022]
Abstract
The prevalence of dementia is increasing in our aging population at an alarming rate. Because of the heterogeneity of clinical presentation and complexity of disease neuropathology, dementia classifications remain controversial. Recently, the National Plan to address Alzheimer’s Disease prioritized Alzheimer’s disease-related dementias to include: Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, and mixed dementias. While each of these dementing conditions has their unique pathologic signature, one common etiology shared among all these conditions is cerebrovascular dysfunction at some point during the disease process. The goal of this comprehensive review is to summarize the current findings in the field and address the important contributions of cerebrovascular, physiologic, and cellular alterations to cognitive impairment in these human dementias. Specifically, evidence will be presented in support of small-vessel disease as an underlying neuropathologic hallmark of various dementias, while controversial findings will also be highlighted. Finally, the molecular mechanisms shared among all dementia types including hypoxia, oxidative stress, mitochondrial bioenergetics, neuroinflammation, neurodegeneration, and blood–brain barrier permeability responsible for disease etiology and progression will be discussed.
Collapse
|
40
|
Carlson JOE, Gatz M, Pedersen NL, Graff C, Nennesmo I, Lindström AK, Gerritsen L. Antemortem Prediction of Braak Stage. J Neuropathol Exp Neurol 2015; 74:1061-70. [PMID: 26469248 PMCID: PMC4610255 DOI: 10.1097/nen.0000000000000251] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
We examined the extent to which tauopathy distribution, as determined by Braak staging, might be predicted by various risk factors in older individuals. The Swedish Twin Registry provided extensive information on neuropsychological function, lifestyle, and cardiovascular risk factors of 128 patients for whom autopsy data including Braak staging were available. Logistic regression was used to develop a prognostic model that targeted discrimination between Braak stages 0 to II and III to VI. The analysis showed that Braak stages III to VI were significantly predicted by having 1 or more APOE ε4 alleles, older age, high total cholesterol, absence of diabetes and cardiovascular disease, and poorer scores on the Wechsler Adult Intelligence Score Information test, verbal fluency, and recognition memory but better verbal recall. The algorithm predicted Braak stages III to VI well (receiver-operating characteristic area under curve, 0.897; 95% confidence interval, 0.842-0.951). Using a cutoff of 50% risk or more, the sensitivity was 85%, the specificity was 70%, and the negative predictive value was 69%. This study demonstrates that tauopathy distribution can be accurately predicted using a combination of antemortem patient data. These results provide further insight into tauopathy development and AD-related disease mechanisms and suggest a prognostic model that predicts the spread of neurofibrillary tangles above the transentorhinal stage.
Collapse
Affiliation(s)
| | - Margaret Gatz
- Karolinska Institutet, Stockholm, Sweden
- University of Southern California, Los Angeles, California
| | - Nancy L. Pedersen
- Karolinska Institutet, Stockholm, Sweden
- University of Southern California, Los Angeles, California
| | | | | | | | - Lotte Gerritsen
- Karolinska Institutet, Stockholm, Sweden
- VU University Medical Centre, Amsterdam, The Netherlands
| |
Collapse
|
41
|
Comparative Incidence of Conformational, Neurodegenerative Disorders. PLoS One 2015; 10:e0137342. [PMID: 26335347 PMCID: PMC4559310 DOI: 10.1371/journal.pone.0137342] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 08/14/2015] [Indexed: 12/12/2022] Open
Abstract
Background The purpose of this study was to identify incidence and survival patterns in conformational neurodegenerative disorders (CNDDs). Methods We identified 2563 reports on the incidence of eight conditions representing sporadic, acquired and genetic, protein-associated, i.e., conformational, NDD groups and age-related macular degeneration (AMD). We selected 245 papers for full-text examination and application of quality criteria. Additionally, data-collection was completed with detailed information from British, Swedish, and Spanish registries on Creutzfeldt-Jakob disease (CJD) forms, amyotrophic lateral sclerosis (ALS), and sporadic rapidly progressing neurodegenerative dementia (sRPNDd). For each condition, age-specific incidence curves, age-adjusted figures, and reported or calculated median survival were plotted and examined. Findings Based on 51 valid reported and seven new incidence data sets, nine out of eleven conditions shared specific features. Age-adjusted incidence per million person-years increased from ≤1.5 for sRPNDd, different CJD forms and Huntington's disease (HD), to 1589 and 2589 for AMD and Alzheimer's disease (AD) respectively. Age-specific profiles varied from (a) symmetrical, inverted V-shaped curves for low incidences to (b) those increasing with age for late-life sporadic CNDDs and for sRPNDd, with (c) a suggested, intermediate, non-symmetrical inverted V-shape for fronto-temporal dementia and Parkinson's disease. Frequently, peak age-specific incidences from 20–24 to ≥90 years increased with age at onset and survival. Distinct patterns were seen: for HD, with a low incidence, levelling off at middle age, and long median survival, 20 years; and for sRPNDd which displayed the lowest incidence, increasing with age, and a short median disease duration. Interpretation These results call for a unified population view of NDDs, with an age-at-onset-related pattern for acquired and sporadic CNDDs. The pattern linking age at onset to incidence magnitude and survival might be explained by differential pathophysiological mechanisms associated with specific misfolded protein deposits.
Collapse
|
42
|
Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus. J Neuropathol Exp Neurol 2015; 74:470-9. [PMID: 25868149 DOI: 10.1097/nen.0000000000000191] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Alzheimer disease (AD)-related pathology was assessed in cortical biopsy samples of 111 patients with idiopathic normal-pressure hydrocephalus. Alzheimer disease hallmark lesions-β-amyloid (Aβ) and hyperphosphorylated tau (HPtau)-were observed in 47% of subjects, a percentage consistent with that for whole-brain assessment reported postmortem in unselected cohorts. Higher-immunostained area fraction of AD pathology corresponded with lower preoperative mini-mental state examination scores. Concomitant Aβ and HPtau pathology, reminiscent of that observed in patients with AD, was observed in 22% of study subjects. There was a significant correlation between Aβ-immunostained area fraction in tissue and Aβ42 (42-amino-acid form of Aβ) in cerebrospinal fluid (CSF). Levels of Aβ42 were significantly lower in CSF in subjects with concomitant Aβ and HPtau pathology compared with subjects lacking pathology. Moreover, a significant correlation between HPtau-immunostained area fraction and HPtau in CSF was noted. Both HPtau and total tau were significantly higher in CSF in subjects with concomitant Aβ and HPtau pathology compared with subjects lacking pathology. The 42-amino-acid form of Aβ (Aβ42) and HPtau in CSF were the most significant predictors of the presence of AD pathology in cortical biopsies. Long-term follow-up studies are warranted to assess whether all patients with idiopathic normal-pressure hydrocephalus with AD pathology progress to AD and to determine the pathologic substrate of idiopathic normal-pressure hydrocephalus.
Collapse
|
43
|
Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimers Dement 2015; 11:986-93. [PMID: 25916563 DOI: 10.1016/j.jalz.2015.03.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Revised: 01/16/2015] [Accepted: 03/06/2015] [Indexed: 10/23/2022]
Abstract
BACKGROUND We evaluated the relationship between florbetapir-F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers. METHODS Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression. RESULTS In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p-tau added discriminative power to FBP PET when classifying HC versus AD. CONCLUSION Based on cross-sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.
Collapse
Affiliation(s)
- Ann Hake
- Eli Lilly and Company, Indianapolis, IN, USA; Department of Neurology Indiana University School of Medicine, Indianapolis, IN, USA.
| | - Paula T Trzepacz
- Eli Lilly and Company, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
| | | | - Peng Yu
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | | | - Elisabeth K Degenhardt
- Eli Lilly and Company, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana University Health Physicians Group, Indiana University Health, Indianapolis, IN, USA
| | | | | |
Collapse
|
44
|
Abner EL, Schmitt FA, Nelson PT, Lou W, Wan L, Gauriglia R, Dodge HH, Woltjer RL, Yu L, Bennett DA, Schneider JA, Chen R, Masaki K, Katz MJ, Lipton RB, Dickson DW, Lim KO, Hemmy LS, Cairns NJ, Grant E, Tyas SL, Xiong C, Fardo DW, Kryscio RJ. The Statistical Modeling of Aging and Risk of Transition Project: Data Collection and Harmonization Across 11 Longitudinal Cohort Studies of Aging, Cognition, and Dementia. OBSERVATIONAL STUDIES 2015; 1:56-73. [PMID: 25984574 PMCID: PMC4431579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Longitudinal cognitive trajectories and other factors associated with mixed neuropathologies (such as Alzheimer's disease with co-occurring cerebrovascular disease) remain incompletely understood, despite being the rule and not the exception in older populations. The Statistical Modeling of Aging and Risk of Transition study (SMART) is a consortium of 11 different high-quality longitudinal studies of aging and cognition (N=11,541 participants) established for the purpose of characterizing risk and protective factors associated with subtypes of age-associated mixed neuropathologies (N=3,001 autopsies). While brain donation was not required for participation in all SMART cohorts, most achieved substantial autopsy rates (i.e., > 50%). Moreover, the studies comprising SMART have large numbers of participants who were followed from intact cognition and transitioned to cognitive impairment and dementia, as well as participants who remained cognitively intact until death. These data provide an exciting opportunity to apply sophisticated statistical methods, like Markov processes, that require large, well-characterized samples. Thus, SMART will serve as an important resource for the field of mixed dementia epidemiology and neuropathology.
Collapse
Affiliation(s)
- E L Abner
- Snders-Brown Center on Aging, University of Kentucky
| | - F A Schmitt
- Oregon Center for Aging & Technology, Oregon Health & Science University
| | - P T Nelson
- Rush Alzheimer's Disease Center, Rush University Medical Center
| | | | - L Wan
- Department of Neurology, Albert Einstein College of Medicine
| | - R Gauriglia
- Department of Laboratory Medicine & Pathology, Mayo Clinic Jacksonville
| | - H H Dodge
- Department of Psychiatry, University of Minnesota
| | - R L Woltjer
- Alzheimer's Disease Research Center, Washington University
| | - L Yu
- School of Public Health and Health Systems, University of Waterloo
| | - D A Bennett
- College of Public Health, University of Kentucky
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Attems J, Neltner JH, Nelson PT. Quantitative neuropathological assessment to investigate cerebral multi-morbidity. ALZHEIMERS RESEARCH & THERAPY 2014; 6:85. [PMID: 25435922 PMCID: PMC4247208 DOI: 10.1186/s13195-014-0085-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The aging brain is characterized by the simultaneous presence of multiple pathologies, and the prevalence of cerebral multi-morbidity increases with age. To understand the impact of each subtype of pathology and the combined effects of cerebral multi-morbidity on clinical signs and symptoms, large clinico-pathological correlative studies have been performed. However, such studies are often based on semi-quantitative assessment of neuropathological hallmark lesions. Here, we discuss some of the new methods for high-throughput quantitative neuropathological assessment. These methods combine increased quantitative rigor with the added technical capacity of computers and networked analyses. There are abundant new opportunities - with specific techniques that include slide scanners, automated microscopes, and tissue microarrays - and also potential pitfalls. We conclude that quantitative and digital neuropathologic approaches will be key resources to further elucidate cerebral multi-morbidity in the aged brain and also hold the potential for changing routine neuropathologic diagnoses.
Collapse
Affiliation(s)
- Johannes Attems
- Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL UK
| | - Janna H Neltner
- Department of Pathology, Division of Neuropathology, University of Kentucky, 800 Limestone Street, Lexington, KY 40536-0230 USA
| | - Peter T Nelson
- Department of Pathology, Division of Neuropathology, University of Kentucky, 800 Limestone Street, Lexington, KY 40536-0230 USA
| |
Collapse
|
46
|
Guzmán-Vélez E, Tranel D. Does bilingualism contribute to cognitive reserve? Cognitive and neural perspectives. Neuropsychology 2014; 29:139-50. [PMID: 24933492 DOI: 10.1037/neu0000105] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
OBJECTIVE Cognitive reserve refers to how individuals actively utilize neural resources to cope with neuropathology to maintain cognitive functioning. The present review aims to critically examine the literature addressing the relationship between bilingualism and cognitive reserve to elucidate whether bilingualism delays the onset of cognitive and behavioral manifestations of dementia. Potential neural mechanisms behind this relationship are discussed. METHOD PubMed and PsycINFO databases were searched (through January 2014) for original research articles in English or Spanish languages. The following search strings were used as keywords for study retrieval: "bilingual AND reserve," "reserve AND neural mechanisms," and "reserve AND multilingualism." RESULTS Growing scientific evidence suggests that lifelong bilingualism contributes to cognitive reserve and delays the onset of Alzheimer's disease symptoms, allowing bilingual individuals affected by Alzheimer's disease to live an independent and richer life for a longer time than their monolingual counterparts. Lifelong bilingualism is related to more efficient use of brain resources that help individuals maintain cognitive functioning in the presence of neuropathology. We propose multiple putative neural mechanisms through which lifelong bilinguals cope with neuropathology. The roles of immigration status, education, age of onset, proficiency, and frequency of language use on the relationship between cognitive reserve and bilingualism are considered. CONCLUSIONS Implications of these results for preventive practices and future research are discussed.
Collapse
|
47
|
Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 2014; 5:88. [PMID: 24795750 PMCID: PMC4005958 DOI: 10.3389/fgene.2014.00088] [Citation(s) in RCA: 491] [Impact Index Per Article: 49.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Accepted: 04/01/2014] [Indexed: 01/17/2023] Open
Abstract
The goal of this review is to discuss how behavioral tests in mice relate to the pathological and neuropsychological features seen in human Alzheimer's disease (AD), and present a comprehensive analysis of the temporal progression of behavioral impairments in commonly used AD mouse models that contain mutations in amyloid precursor protein (APP). We begin with a brief overview of the neuropathological changes seen in the AD brain and an outline of some of the clinical neuropsychological assessments used to measure cognitive deficits associated with the disease. This is followed by a critical assessment of behavioral tasks that are used in AD mice to model the cognitive changes seen in the human disease. Behavioral tests discussed include spatial memory tests [Morris water maze (MWM), radial arm water maze (RAWM), Barnes maze], associative learning tasks (passive avoidance, fear conditioning), alternation tasks (Y-Maze/T-Maze), recognition memory tasks (Novel Object Recognition), attentional tasks (3 and 5 choice serial reaction time), set-shifting tasks, and reversal learning tasks. We discuss the strengths and weaknesses of each of these behavioral tasks, and how they may correlate with clinical assessments in humans. Finally, the temporal progression of both cognitive and non-cognitive deficits in 10 AD mouse models (PDAPP, TG2576, APP23, TgCRND8, J20, APP/PS1, TG2576 + PS1 (M146L), APP/PS1 KI, 5×FAD, and 3×Tg-AD) are discussed in detail. Mouse models of AD and the behavioral tasks used in conjunction with those models are immensely important in contributing to our knowledge of disease progression and are a useful tool to study AD pathophysiology and the resulting cognitive deficits. However, investigators need to be aware of the potential weaknesses of the available preclinical models in terms of their ability to model cognitive changes observed in human AD. It is our hope that this review will assist investigators in selecting an appropriate mouse model, and accompanying behavioral paradigms to investigate different aspects of AD pathology and disease progression.
Collapse
Affiliation(s)
- Scott J Webster
- Sanders-Brown Center on Aging, University of Kentucky Lexington, KY, USA
| | - Adam D Bachstetter
- Sanders-Brown Center on Aging, University of Kentucky Lexington, KY, USA
| | - Peter T Nelson
- Sanders-Brown Center on Aging, University of Kentucky Lexington, KY, USA ; Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of Kentucky Lexington, KY, USA
| | - Frederick A Schmitt
- Sanders-Brown Center on Aging, University of Kentucky Lexington, KY, USA ; Department of Neurology, University of Kentucky Lexington, KY, USA
| | - Linda J Van Eldik
- Sanders-Brown Center on Aging, University of Kentucky Lexington, KY, USA ; Department of Anatomy and Neurobiology, University of Kentucky Lexington, KY, USA
| |
Collapse
|
48
|
Alzheimer's disease‐related plaques in nondemented subjects. Alzheimers Dement 2014; 10:522-9. [DOI: 10.1016/j.jalz.2012.12.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 10/30/2012] [Accepted: 12/20/2012] [Indexed: 11/20/2022]
|
49
|
Jellinger KA, Attems J. Neuropathological approaches to cerebral aging and neuroplasticity. DIALOGUES IN CLINICAL NEUROSCIENCE 2013. [PMID: 23576887 PMCID: PMC3622466 DOI: 10.31887/dcns.2013.15.1/kjellinger] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Cerebral aging is a complex and heterogenous process related to a large variety of molecular changes involving multiple neuronal networks, due to alterations of neurons (synapses, axons, dendrites, etc), particularly affecting strategically important regions, such as hippocampus and prefrontal areas. A substantial proportion of nondemented, cognitively unimpaired elderly subjects show at least mild to moderate, and rarely even severe, Alzheimer-related lesions, probably representing asymptomatic preclinical Alzheimer's disease, and/or mixed pathologies. While the substrate of resilience to cognitive decline in the presence of abundant pathologies has been unclear, recent research has strengthened the concept of cognitive or brain reserve, based on neuroplasticity or the ability of the brain to manage or counteract age-related changes or pathologies by reorganizing its structure, connections, and functions via complex molecular pathways and mechanisms that are becoming increasingly better understood. Part of neuroplasticity is adult neurogenesis in specific areas of the brain, in particular the hippocampal formation important for memory function, the decline of which is common even in “healthy” aging. To obtain further insights into the mechanisms of brain plasticity and adult neurogenesis, as the basis for prevention and potential therapeutic options, is a major challenge of modern neurosciences.
Collapse
|
50
|
Gardner A, Iverson GL, McCrory P. Chronic traumatic encephalopathy in sport: a systematic review. Br J Sports Med 2013; 48:84-90. [PMID: 23803602 DOI: 10.1136/bjsports-2013-092646] [Citation(s) in RCA: 122] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To provide a critical review of chronic traumatic encephalopathy (CTE) by considering the range of clinical presentations, neuropathology and the strength of evidence for CTE as a distinct syndrome. DATA SOURCES Seven electronic databases were searched using a combination of MeSH terms and key words to identify relevant articles. REVIEW METHODS Specific inclusion and exclusion criteria were used to select studies for review. Data extracted where present included study population, exposure/outcome measures, clinical data, neurological examination findings, cognitive assessment, investigation results and neuropathology results. RESULTS The data from 158 published case studies were reviewed. Critical differences between the older descriptions of CTE (the 'classic' syndrome) and the recent descriptions (the 'modern' syndrome) exist in the age of onset, natural history, clinical features, pathological findings and diagnostic criteria, which suggests that modern CTE is a different syndrome. The methodology of the current studies does not allow determination of aetiology or risk factors. CONCLUSIONS The clinicopathological differences between the 'classic' CTE syndrome and the 'modern' syndrome suggest that the new syndrome needs a different nomenclature. Further research is required to clearly define the clinical phenotype of the modern CTE syndrome and establish the underlying aetiology. Future research needs to address these issues through large-scale, prospective clinicopathological studies.
Collapse
Affiliation(s)
- Andrew Gardner
- Centre for Translational Neuroscience and Mental Health, School of Medicine and Public Health, University of Newcastle, , Callaghan, New South Wales, Australia
| | | | | |
Collapse
|